Browse MMP9

Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF00040 Fibronectin type II domain
PF00045 Hemopexin
PF00413 Matrixin
PF01471 Putative peptidoglycan binding domain
Function

May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001667 ameboidal-type cell migration
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001836 release of cytochrome c from mitochondria
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0008637 apoptotic mitochondrial changes
GO:0010466 negative regulation of peptidase activity
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0010951 negative regulation of endopeptidase activity
GO:0022617 extracellular matrix disassembly
GO:0022898 regulation of transmembrane transporter activity
GO:0030099 myeloid cell differentiation
GO:0030198 extracellular matrix organization
GO:0030225 macrophage differentiation
GO:0030335 positive regulation of cell migration
GO:0030574 collagen catabolic process
GO:0032092 positive regulation of protein binding
GO:0032409 regulation of transporter activity
GO:0032410 negative regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032413 negative regulation of ion transmembrane transporter activity
GO:0032963 collagen metabolic process
GO:0033002 muscle cell proliferation
GO:0034762 regulation of transmembrane transport
GO:0034763 negative regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034766 negative regulation of ion transmembrane transport
GO:0035987 endodermal cell differentiation
GO:0038127 ERBB signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0043062 extracellular structure organization
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043271 negative regulation of ion transport
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043388 positive regulation of DNA binding
GO:0043393 regulation of protein binding
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044706 multi-multicellular organism process
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045861 negative regulation of proteolysis
GO:0048013 ephrin receptor signaling pathway
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050900 leukocyte migration
GO:0051051 negative regulation of transport
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051101 regulation of DNA binding
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051546 keratinocyte migration
GO:0051547 regulation of keratinocyte migration
GO:0051549 positive regulation of keratinocyte migration
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090199 regulation of release of cytochrome c from mitochondria
GO:0090200 positive regulation of release of cytochrome c from mitochondria
GO:0097193 intrinsic apoptotic signaling pathway
GO:1900120 regulation of receptor binding
GO:1900122 positive regulation of receptor binding
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
GO:1904062 regulation of cation transmembrane transport
GO:1904063 negative regulation of cation transmembrane transport
GO:1904705 regulation of vascular smooth muscle cell proliferation
GO:1904707 positive regulation of vascular smooth muscle cell proliferation
GO:1990874 vascular smooth muscle cell proliferation
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2000147 positive regulation of cell motility
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
GO:2001257 regulation of cation channel activity
GO:2001258 negative regulation of cation channel activity
GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:2001268 negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005518 collagen binding
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG hsa04668 TNF signaling pathway
hsa04670 Leukocyte transendothelial migration
hsa04915 Estrogen signaling pathway
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-422475: Axon guidance
R-HSA-1442490: Collagen degradation
R-HSA-1474290: Collagen formation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6798695: Neutrophil degranulation
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-1433557: Signaling by SCF-KIT
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MMP9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MMP9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23509357Breast CarcinomaPromote immunity (infiltration)In addition to increased generation of endostatin, AdMMP-9 promoted an antitumor immune response by inducing massive neutrophil infiltration.
29628320lung adenocarcinomaPromote immunityIn the RNA-Seq analysis, MMP9 and VEGFA showed higher levels in wild-type EGFR than in mutant cases.
28754674Breast CarcinomaInhibit immunitydipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression. Similarly, MMP9 inhibition reduced neoplastic angiogenesis and significantly decreased local and metastatic tumor growth.
16891318GlioblastomaPromote immunityYet again, MP inhibition by the broad spectrum inhibitors GM 6001 or MMP inhibitor III selectively enhanced the expression of MICA and ULBP2 on the surface of LNT- 229 cells but not of other NKG2DL (Fig. 4A). For MICA, this effect was significantly more prominent on control than on TGF-b1/2 siRNA cells. Thus, escape from NKG2D-mediated immune surveillance of malignant gliomas in vivo may be promoted by the inhibition of MICA and ULBP2 expression via an autocrine TGF-beta loop and by MP-dependent shedding from the cell surface.
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MMP9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MMP9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7930.186
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1350.957
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.2680.47
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.4830.0969
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5590.471
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3750.642
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0130.987
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2160.898
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1270.942
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2840.885
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1190.966
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2080.479
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MMP9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.214.3-8.10.586
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MMP9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MMP9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMMP9
Namematrix metallopeptidase 9
Aliases CLG4B; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; MANDP2; ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MMP9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MMP9.
ID Name Drug Type Targets #Targets
DB00143GlutathioneSmall MoleculeAKR1B1, CYP3A4, ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GP ......41
DB00786MarimastatSmall MoleculeMMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......23
DB01017MinocyclineSmall MoleculeALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA7
DB01197CaptoprilSmall MoleculeACE, BDKRB1, LTA4H, MMP2, MMP95
DB01296GlucosamineSmall MoleculeIFNG, MMP9, NFKB2, TNF4
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB019492-Amino-N,3,3-TrimethylbutanamideSmall MoleculeMMP91
DB036832-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic AcidSmall MoleculeMMP91
DB05387AE-941Small MoleculeMMP12, MMP2, MMP93
DB05495PG-530742Small MoleculeMMP91
DB071175-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONESmall MoleculeMMP91
DB07246(2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDESmall MoleculeMMP91
DB07285(3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACIDSmall MoleculeMMP91